Details of the Drug

General Information of Drug (ID: DMAEZB1)

• Drug Name: PMID25514969-Compound-9
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 372.3
  Logarithm of the Partition Coefficient (xlogp); 3.9
  Rotatable Bond Count (rotbonds); 3
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 7
• Chemical Identifiers:
  Formula: C18H11F3N4O2
  IUPAC Name: 8-(1,3-oxazol-5-yl)-N-phenyl-6-(trifluoromethyl)imidazo[1,2-a]pyridine-3-carboxamide
  Canonical SMILES: C1=CC=C(C=C1)NC(=O)C2=CN=C3N2C=C(C=C3C4=CN=CO4)C(F)(F)F
  InChI: InChI=1S/C18H11F3N4O2/c19-18(20,21)11-6-13(15-8-22-10-27-15)16-23-7-14(25(16)9-11)17(26)24-12-4-2-1-3-5-12/h1-10H,(H,24,26)
  InChIKey: SNIXWKGBBMUCPJ-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 118379029
  TTD ID: D09RTV

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cholesterol 24-hydroxylase (CYP46A1)	TT4EB85	CP46A_HUMAN	Inhibitor	[1]

References

• [1] Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7.